{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:36:25Z","timestamp":1765038985945},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1016\/s0149-2918(03)80171-6","type":"journal-article","created":{"date-parts":[[2003,7,16]],"date-time":"2003-07-16T13:35:31Z","timestamp":1058362531000},"page":"1806-1825","source":"Crossref","is-referenced-by-count":40,"title":["Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States"],"prefix":"10.1016","volume":"25","author":[{"given":"Kristen","family":"Migliaccio-Walle","sequence":"first","affiliation":[]},{"given":"Denis","family":"Getsios","sequence":"additional","affiliation":[]},{"given":"J.Jaime","family":"Caro","sequence":"additional","affiliation":[]},{"given":"Khajak J","family":"Ishak","sequence":"additional","affiliation":[]},{"given":"Judith A","family":"O'Brien","sequence":"additional","affiliation":[]},{"given":"George","family":"Papadopoulos","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/S0149-2918(03)80171-6_BIB1","first-page":"135","article-title":"Economic research on Alzheimer disease: A review of the literature","volume":"11","author":"Ernst","year":"1997","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00019053-200018030-00002","article-title":"The epidemic of Alzheimer's disease. How can we manage the costs?","volume":"18","author":"Johnson","year":"2000","journal-title":"PharmacoEconomics"},{"issue":"Suppl 1","key":"10.1016\/S0149-2918(03)80171-6_BIB3","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1212\/WNL.51.1_Suppl_1.S53","article-title":"Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention","volume":"51","author":"Dunkin","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1377\/hlthaff.12.2.164","article-title":"The economic burden of Alzheimer's disease care","volume":"12","author":"Rice","year":"1993","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl 4","key":"10.1016\/S0149-2918(03)80171-6_BIB5","first-page":"S6","article-title":"The economic impact of Alzheimer's disease","volume":"43","author":"Max","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00019053-199609010-00002","article-title":"The cost of Alzheimer's disease. Will drug treatment ease the burden?","volume":"9","author":"Max","year":"1996","journal-title":"PharmacoEconomics"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1532-5415.2002.50065.x","article-title":"The impact of symptom severity on the cost of Alzheimer's disease","volume":"50","author":"Small","year":"2002","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB8_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/j.1875-9114.1998.tb03880.x","article-title":"Economic considerations in Alzheimer's disease","volume":"18","author":"Meek","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB8_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/j.1875-9114.1998.tb03880.x","article-title":"Economic considerations in Alzheimer's disease","volume":"18","author":"Meek","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archneur.1997.00550180013006","article-title":"Cognitive function and the costs of Alzheimer disease. An exploratory study","volume":"54","author":"Ernst","year":"1997","journal-title":"Arch Neurol."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB10","first-page":"457","article-title":"Relation between severity of Alzheimer's disease and costs of caring","volume":"159","author":"Hux","year":"1998","journal-title":"Can Med Assoc J."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB11","first-page":"S1139","article-title":"The pharmacoeconomics of Alzheimer's disease","volume":"6922","author":"Fillit","year":"2000","journal-title":"Am J Managed Care"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002093-200007000-00006","article-title":"The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients","volume":"14","author":"Martin","year":"2000","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0149-2918(00)90011-0","article-title":"Medical services utilization and charge comparisons between elderly patients with and without Alzheimer's disease in a managed care organization","volume":"22","author":"Richards","year":"2000","journal-title":"Clin Ther."},{"issue":"Suppl 2","key":"10.1016\/S0149-2918(03)80171-6_BIB14","first-page":"S9","article-title":"Assessing the societal impact of acetylcholinesterase inhibitor therapies","volume":"13","author":"Winblad","year":"1999","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB15","series-title":"Drug Treatments for Alzheimer's Disease. III. A Review of Pharmacoeconomic Evaluations","author":"Shukla","year":"2000"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0944-7113(00)80066-5","article-title":"Cholinesterase inhibitors and Ginkgo extracts\u2014are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration","volume":"6","author":"Wettstein","year":"1999","journal-title":"Phytomedicine"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB17","series-title":"The Cochrane Library","article-title":"Rivastigmine for Alzheimer's disease (Cochrane review)","author":"Birks","year":"2000"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB18","series-title":"The Cochrane Library","article-title":"Donepezil for mild and moderate Alzheimer's disease (Cochrane review)","author":"Birks","year":"2000"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB19","series-title":"The Cochrane Library","article-title":"Galantamine for Alzheimer's disease (Cochrane review)","author":"Olin","year":"2001"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0149-2918(98)80145-8","article-title":"An economic evaluation of donepezil in the treatment of Alzheimer's disease","volume":"20","author":"Small","year":"1998","journal-title":"Clin Ther."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","article-title":"Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease","volume":"52","author":"Neumann","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB22","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0149-2918(00)87246-X","article-title":"Donepezil use in managed Medicare: Effect on health care costs and utilization","volume":"21","author":"Fillit","year":"1992","journal-title":"Clin Ther."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00019053-200017040-00005","article-title":"Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine","volume":"17","author":"Hauber","year":"2000","journal-title":"PharmacoEconomics"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: A review of its use in Alzheimer's disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-0404.2000.00310.x","article-title":"Galantamine is an allosterically potentiating ligand of the human alpha4\/beta2 nAChR","volume":"176","author":"Samochocki","year":"2000","journal-title":"Acta Neurol Scand Suppl."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB26","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month, randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB27","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/S0149-2918(03)80171-6_BIB29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000051228","article-title":"Galantamine: Additional benefits to patients wiht Alzheimer's disease","volume":"11","author":"Lilienfeld","year":"2000","journal-title":"Dementia Geriatr Cogn Disord."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00019053-200220130-00005","article-title":"Galantamine: A pharmacoeconomic review of its use in Alzheimer's disease","volume":"20","author":"Lyseng-Williamson","year":"2002","journal-title":"PharmacoEconomics"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB32","first-page":"1","article-title":"Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technol Assess."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0149-2918(00)89012-8","article-title":"Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine","volume":"22","author":"Hauber","year":"2000","journal-title":"Clin Ther."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1532-5415.2000.tb04720.x","article-title":"Predicting 10-year care requirements for older people with suspected Alzheimer's disease","volume":"48","author":"Kinosian","year":"2000","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/02813439209014059","article-title":"Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders","volume":"10","author":"Wimo","year":"1992","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/gps.930080906","article-title":"Predictors of nursing home placement in patients with Alzheimer's disease","volume":"8","author":"Haupt","year":"1993","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.57.6.964","article-title":"Assessment of Health Economics in Alzheimer's Disease (AHEAD) based on need for full-time care","volume":"57","author":"Caro","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB38","article-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.277.10.806","article-title":"Predicting time to nursing home care and death in individuals with Alzheimer disease","volume":"277","author":"Stern","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB40","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.48.6.1511","article-title":"The Alzheimer's Disease Assessment Scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials","volume":"48","author":"Doraiswamy","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB43","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB44","author":"US Department of Labor, Bureau of Labor Statistics"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB45","series-title":"Medicare and Medicare Statistical Supplement","author":"Health Care Financing Review","year":"1999"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB46","series-title":"Homecare Salary and Benefits Report, 1999\u20132000","author":"National Association for Home Care","year":"1999"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB47","first-page":"433","article-title":"Differences across payors in charges for agency-based home health services: Evidence from the National Home and Hospice Care Survey","volume":"32","author":"Freedman","year":"1997","journal-title":"Health Serv Res."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB48","volume":"Vol 47","author":"US Department of Labor","year":"2000"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB49","series-title":"State Assisted Living Policy: 2000","author":"Mollica","year":"2000"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB50","year":"2002"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB51","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.276.15.1253","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/S0149-2918(03)80171-6_BIB52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000051229","article-title":"Galantamine: Therapeutic effects beyond cognition","volume":"11","author":"Blesa","year":"2000","journal-title":"Dementia Geriatr Cogn Disord."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E","article-title":"Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five year's therapy using donepezil","volume":"13","author":"Stewart","year":"1998","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB54","first-page":"870","article-title":"Factors affecting the economic attractiveness of cognitive enhacers in Alzheimer's disease","volume":"38","author":"Lanct\u00f4t","year":"1998","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1532-5415.1999.tb02572.x","article-title":"Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada","volume":"47","author":"O'Brien","year":"1999","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00019053-199916020-00005","article-title":"Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach","volume":"16","author":"Fenn","year":"1999","journal-title":"PharmacoEconomics"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB57","first-page":"2525","article-title":"Guidelines for managing Alzheimer's disease: Part II. Treatment","volume":"65","author":"Cummings","year":"2002","journal-title":"Am Fam Phys."},{"key":"10.1016\/S0149-2918(03)80171-6_BIB58","series-title":"Poster presented at: Springfield Symposium on Advances in Alzheimer's Therapy","article-title":"First head-to-head study comparing the tolerability and safety of donepezil and galantamine","author":"Jones","year":"2002"},{"key":"10.1016\/S0149-2918(03)80171-6_BIB59","series-title":"Poster presented at: 6th Congress of the European Federation of Neurological Societies","article-title":"Galantamine demonstrates superior efficacy on attention and MMSE compared with donepezil in patients with Alzheimer's disease actively treated for 52 weeks: An initial analysis","author":"Truyen","year":"2002"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291803801716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291803801716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T16:46:20Z","timestamp":1623170780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291803801716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0149291803801716"],"URL":"https:\/\/doi.org\/10.1016\/s0149-2918(03)80171-6","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}